Clinical Trial Update: Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether adding interleukin-2 to sorafenib improves outcomes as first-line therapy in advanced renal cell carcinoma; the study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Italian Trial in Medical Oncology | Conditions: Metastatic Disease, Renal Cell Carcinoma | Phase 2 | Status: COMPLETED